Klinik und Poliklinik
für Innere Medizin II
Klinik und Poliklinik für Innere Medizin II
Direktor: Univ.-Prof. Dr. med. Roland. M. Schmid
direktion.med2@mri.tum.de

Studien der Onkologischen Tagesklinik

Zentrales Anliegen unserer Tagesklinik ist eine personalisierte Tumortherapie und die Durchführung innovativer klinischer Studien in der Onkologie. Durch die international und national hervorragende Vernetzung der Mitarbeiter besteht vielfältiger Zugang zu Therapiestudien für alle wesentlichen Tumorerkrankungen des Gastrointestinaltraktes, der Leber und des Pankreas. Dadurch ist es möglich, im Rahmen von Studien neue Medikamente (targeted therapy) und innovative Therapieansätze zu untersuchen und Biomarker bezüglich Therapieansprechen und Prognoseabschätzung zu evaluieren. Derzeit bestehen neuartige Therapiekonzepte für das kolorektale Karzinom, Pankreaskarzinom, Gallengangskarzinom, Leberzellkarzinom, Magenkarzinom und Ösophaguskarzinom.

Hepatozelluläres Karzinom (HCC)

AIO-HEP-0217 IMMUTACE
first line

A Phase II single-arm, open-label study of transarterial chemo-embolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

 

REACH-2
second line

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy other than Sorafenib

Cholangiozelluläres Karzinom (CCC)

PCI 203-18
first line

A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma

 

AIO-HEP-0116 NALIRICC
second line

A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine and paltinum-based therapies

Magenkarzinom

AIO-STO-0215 Renaissance
first line

Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagosgastric junction - a phase III trial of AIO/CAO-V/CAOGI

 

AIO-STO-0317 DANTE
first line

A randomized, open-label Phase II efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039)

 

AIO-STO-0415 RAMIRIS
second line

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy

Pankreaskarzinom

HEAT
adjuvant

A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine alone (Arm G) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH)

 

AIO-PAK-0114 ALPACA
first line

Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study

 

AIO-PAK-0116 PANTHEON
second line

A health service research study to investigate survival of metastatic pancreatic cancer patients after sequential chemotherapy: An AIO phase II cross over trial


Kontakt und Ansprechpartner

Studiensekretariat:
Jens Zimmermann
Klinik und Poliklinik für Innere Medizin II
Klinikum rechts der Isar der TUM
Ismaningerstr. 22, 81675 München
Tel.: (0 89) 41 40 - 67 06
Fax: (0 89) 41 40 - 75 55

Mail: jens-peter.zimmermann@mri.tum.de